digoxin complex with o-nitrophenyl-β-D-galactopyranoside.

**10.** The immunoassay of claim **8** wherein the measurement step (c) is performed by contacting the eluted β-galactosidase labeled, $F(ab')_2$ anti-digoxin antibody/-digoxin complex with o-nitrophenyl-β-D-galactopyranoside.

**11.** A competitive immunoassay for the measurement of digoxin in a test sample, said assay comprising the sequential steps of:

(a) forming a reaction mixture by contacting a sample suspected of containing digoxin with a molar excess of ouabain immobilized on a solid phase;

(b) contacting the reaction mixture with a labeled, monovalent or divalent anti-digoxin antibody, said antibody being in immunochemical excess over digoxin, but in immunochemical deficiency relative to ouabain;

(c) allowing a reaction to take place whereby a fraction of the antibody forms a first complex with the digoxin and a second fraction forms a complex with the immobilized ouabain;

(d) separating the first fraction from the second fraction; and

(e) measuring the amount of label present in either the first or the second fraction.

**12.** The immunoassay of claim **11** wherein the label is an enzyme, radioisotope, chromophore or fluorophore.

**13.** The immunoassay of claim **11** wherein the monovalent antibody is an Fab fragment or Fab' fragment.

**14.** The immunoassay of claim **11** wherein the divalent antibody is an $F(ab')_2$ fragment.

**15.** The immunoassay of claim **11** wherein the solid phase is beaded agarose, beaded dextran, polyacrylamide or glass.

**16.** The immunoassay of claim **11** wherein the solid phase is beaded dextran, the monovalent antibody is an Fab' fragment and the label is β-galactosidase.

**17.** The immunoassay of claim **11** wherein the solid phase is beaded dextran, the monovalent antibody is an $F(ab')_2$ fragment and the label is β-galactosidase.

**18.** The immunoassay of claim **16** wherein the measurement step (e) is performed by contacting the fraction to be measured with o-nitrophenyl-β-D-galactopyranoside.

**19.** The immunoassay of claim **17** wherein the measurement step (e) is performed by contacting the fraction to be measured with o-nitrophenyl-β-D-galactopyranoside.

**20.** A test kit for measuring the amount of digoxin in a liquid sample, comprising:

(a) a labeled anti-digoxin antibody; and

(b) a solid phase having ouabain bound thereto; and

(c) directions for the use of said kit.

* * * * *